Ingenuity® Systems IPA® Workshop at ASHG
Due to high interest, we will not be taking any more pre-registrations for this session at ASHG. If you are interested in attending, please still come as we will accommodate as many walk-ins as possible. The IPA Workshop video recording will be available after the show as well.
Predicting and understanding the molecular basis of disease through transcriptomics data analysis using Ingenuity Pathway Analysis (IPA)
Wednesday, October 23, 12:30PM - 2PM
Boston Convention and Exhibition Center, Room 051, Exhibit Level
Comprehensive network and pathway analysis of RNA sequencing of triple negative breast cancers
RNA-sequencing technology provides an abundance of data on the transcriptional landscape of cells and tissues presenting a daunting task of interpreting this data in biological contexts. In this workshop, we will be presenting data on RNA-sequencing of triple-negative breast cancers (TNBCs) compared to microdissected normal breast tissues. TNBCs account for 15% of all breast cancers cases in the United States and are defined by an absence of actionable therapeutic targets (Estrogen Receptor-, Progesterone Receptor-, Human Epidermal Growth Factor Receptor-2-). Because of the absence of therapeutic targets, these patients on average have a poorer overall survival compared to other breast cancer subtypes. Using RNA-Seq and IPA Spring/summer release 2013, we demonstrate how comprehensive network and pathway analysis revealed novel insights into tumor biology of this disease and has informed rational drug targeting for therapeutic development. This workshop will include a live demonstration of recently released features in IPA including upstream regulator and causal network analysis.
Speakers:
Dr. Milan Radovich, Division of Surgery,
Indiana University School of Medicine
Dr. Jean-Noel Billaud,
Ingenuity Systems
Please send all questions to marketing@ingenuity.com.